ArticleAnnals of surgery2019
RAS Mutation Clinical Risk Score to Predict Survival After Resection of Colorectal Liver Metastases.
Article in Annals of surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04898504 (EXtended CriteriA Treatment for LIver Metastases With Heavy Tumour BURden 1 + 2), which is not on this map. Cited by 118 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
EXtended CriteriA Treatment for LIver Metastases With Heavy Tumour BURden 1 + 2
Who cites it
118 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- A Model to Predict Treatment Failure in Patients Undergoing Upfront Surgery for Resectable Colorectal Liver Metastases.Annals of surgical oncology · 2023Trial
- Biological Resectability in Colorectal Liver Metastases: A Nomogram-Based Continuous Risk Model to Define Borderline Disease.Annals of gastroenterological surgery · 2026Article
- CT-based radiomics improves survival prediction in colorectal liver metastases: beyond clinical scores.Updates in surgery · 2026Article
- A Comparison of 11 Clinical Risk Scores for Prediction of Survival After Curative-Intent Resection of Colorectal Liver Metastases.Annals of surgical oncology · 2026Article
- Optimal patient selection beyond the current selection criteria for liver transplantation for unresectable colorectal liver metastasis.Surgery today · 2026Review
- Circulating Tumor DNA Dynamics in Patients with Liver-Limited Metastatic Colorectal Cancer Resected after First-Line Systemic Treatment.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- CT radiomics for survival risk stratification in resectable colorectal liver metastases: a multi-centre study.Scientific reports · 2026Article
- Interplay of Tumor Morphology and Biology with Postoperative Complications: Prognostic Implications After Resection of Colorectal Liver Metastasis.Annals of surgical oncology · 2026Article
- Predicting histopathological growth patterns and prognosis of colorectal liver metastases using MRI.European radiology · 2026Article
- New prognostic and predictive scoring systems for colorectal cancer liver metastases.ESMO open · 2026Review
- Histopathologic growth patterns as prognostic factor for survival in patients with colorectal liver metastases.Radiology and oncology · 2026Article
- Review
- Worse Survival in Co-Altered RAS-TP53 Patients With Resected Colorectal Liver Metastases.Annals of surgical oncology · 2026Article
- Real-World Survival Outcomes Following Metastasectomy in RAS Wild-Type mCRC: Insights from a Multicentre National Cohort Study.Journal of clinical medicine · 2026Article
- Proteogenomic Characterization Reveals Metabolic Vulnerabilities and Aberrant Phosphorylation in Colorectal Metastasis to Liver.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Integrated radiomics and machine learning approach for ras mutation status prediction in colorectal liver metastases.La Radiologia medica · 2026Article
- A clinical-molecular nomogram for predicting early recurrence following resection of initially unresectable colorectal liver metastases.Therapeutic advances in medical oncology · 2026Article
- HOXA13 overexpression is associated with poor prognosis in colorectal liver metastasesSurgical oncology insight · 2025Article
- The influence of AI on surgical and ablative treatments for colorectal liver metastases: a review of the current literature.Insights into imaging · 2025Review
58 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
22 authors.
Funding
Abstract
objectiveTo determine the impact of RAS mutation status on the traditional clinical score (t-CS) to predict survival after resection of colorectal liver metastases (CLM).
backgroundThe t-CS relies on the following factors: primary tumor nodal status, disease-free interval, number and size of CLM, and carcinoembryonic antigen level. We hypothesized that the addition of RAS mutation status could create a modified clinical score (m-CS) that would outperform the t-CS.
methodsPatients who underwent resection of CLM from 2005 through 2013 and had RAS mutation status and t-CS factors available were included. Multivariate analysis was used to identify prognostic factors to include in the m-CS. Log-rank survival analyses were used to compare the t-CS and the m-CS. The m-CS was validated in an international multicenter cohort of 608 patients.
resultsA total of 564 patients were eligible for analysis. RAS mutation was detected in 205 (36.3%) of patients. On multivariate analysis, RAS mutation was associated with poor overall survival, as were positive primary tumor lymph node status and diameter of the largest liver metastasis >50 mm. Each factor was assigned 1 point to produce a m-CS. The m-CS accurately stratified patients by overall and recurrence-free survival in both the initial patient series and validation cohort, whereas the t-CS did not.
conclusionsModifying the t-CS by replacing disease-free interval, number of metastases, and CEA level with RAS mutation status produced an m-CS that outperformed the t-CS. The m-CS is therefore a simple validated tool that predicts survival after resection of CLM.
Indexed as
Identifiers
28549012What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.